MIM
ISEE

Monashee Investment Management’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Monashee Investment Management’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-150,000
Closed -$765K – 287
2020
Q2 		$765K Buy
+150,000
New +$625K 0.11% 143

Other funds holding ISEE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Monashee Investment Management's ISEE Position: Q3 2020 in Review

Monashee Investment Management sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2020, closing a stake of 150,000 shares — an estimated $765K sold.

Monashee Investment Management first reported a position in ISEE in Q2 2020 and held it in 1 quarter. The position peaked at $765K in Q2 2020. 101 funds tracked by Wall St. Rank hold ISEE as of Q3 2020.

  • Monashee Investment Management reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Monashee Investment Management sold 150,000 IVERIC bio, Inc. Common Stock shares in Q3 2020, an estimated $765K.
  • Monashee Investment Management first reported a position in IVERIC bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Monashee Investment Management's IVERIC bio, Inc. Common Stock position peaked at $765K in Q2 2020.
  • 101 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2020.

Based on Monashee Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.